Plaizier MA - Search Results

1

Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.

de Bree R, Roos JC, Plaizier MA, Quak JJ, van Kamp GJ, den Hollander W, Snow GB, van Dongen GA. de Bree R, et al. Among authors: plaizier ma. Br J Cancer. 1997;75(7):1049-60. doi: 10.1038/bjc.1997.179. Br J Cancer. 1997. PMID: 9083342 Free PMC article.

2

Distribution and kinetics of 131I-labeled human IgM monoclonal antibody 16.88 in patients with advanced colorectal cancer.

Roos JC, Plaizier MA, van Lingen A, Haisma HJ, den Hollander W, Martens HJ, Nauta JJ, Dejager RL, Teule GJ, Boven E. Roos JC, et al. Among authors: plaizier ma. In Vivo. 1993 Nov-Dec;7(6A):503-9. In Vivo. 1993. PMID: 8193268

3

Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients.

Haisma HJ, Pinedo HM, Kessel MA, van Muijen M, Roos JC, Plaizier MA, Martens HJ, DeJager R, Boven E. Haisma HJ, et al. Among authors: plaizier ma. J Natl Cancer Inst. 1991 Dec 18;83(24):1813-9. doi: 10.1093/jnci/83.24.1813. J Natl Cancer Inst. 1991. PMID: 1744925

4

Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies.

Plaizier MA, Roos JC, Teule GJ, van Dieren EB, den Hollander W, Haisma HJ, DeJager RL, van Lingen A. Plaizier MA, et al. Eur J Nucl Med. 1994 Mar;21(3):216-22. doi: 10.1007/BF00188669. Eur J Nucl Med. 1994. PMID: 8200389

5

Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.

van Zanten-Przybysz I, Molthoff CF, Roos JC, Plaizier MA, Visser GW, Pijpers R, Kenemans P, Verheijen RH. van Zanten-Przybysz I, et al. Among authors: plaizier ma. J Nucl Med. 2000 Jul;41(7):1168-76. J Nucl Med. 2000. PMID: 10914906 Free article.

6

Absorbed dose distribution of the auger emitters 67GA and 125I and the beta-emitters 67CU, 90Y, 131I, and 186RE as a function of tumor size, uptake, and intracellular distribution.

van Dieren EB, Plaizier MA, van Lingen A, Roos JC, Barendsen GW, Teule GJ. van Dieren EB, et al. Among authors: plaizier ma. Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):197-204. doi: 10.1016/s0360-3016(96)00280-5. Int J Radiat Oncol Biol Phys. 1996. PMID: 8823276

7

High-dose gallium-67 therapy in patients with relapsed acute leukaemia: a feasibility study.

Jonkhoff AR, Plaizier MA, Ossenkoppele GJ, Teule GJ, Huijgens PC. Jonkhoff AR, et al. Among authors: plaizier ma. Br J Cancer. 1995 Dec;72(6):1541-6. doi: 10.1038/bjc.1995.544. Br J Cancer. 1995. PMID: 8519674 Free PMC article. Clinical Trial.

8

Calculation of the radiation dose at a bone-to-marrow interface.

van Dieren EB, Plaizier MA, Roos JC, Teule GJ, van Lingen A. van Dieren EB, et al. Among authors: plaizier ma. J Nucl Med. 1992 Oct;33(10):1915-6. J Nucl Med. 1992. PMID: 1403167 Free article. No abstract available.

9

Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer.

Dragoiescu C, Hoekstra OS, Kuik DJ, Lips P, Plaizier MA, Rodrigus PT, Huijsmans DA, Ribot JG, Kuijpens J, Coebergh JW, Teule GJ. Dragoiescu C, et al. Among authors: plaizier ma. Clin Endocrinol (Oxf). 2003 Apr;58(4):451-5. doi: 10.1046/j.1365-2265.2003.01738.x. Clin Endocrinol (Oxf). 2003. PMID: 12641628

10

Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line.

Geldof AA, Plaizier MA, Duivenvoorden I, Ringelberg M, Versteegh RT, Newling DW, Teule GJ. Geldof AA, et al. Among authors: plaizier ma. J Cancer Res Clin Oncol. 2003 Mar;129(3):175-82. doi: 10.1007/s00432-002-0412-8. Epub 2003 Mar 18. J Cancer Res Clin Oncol. 2003. PMID: 12684891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters